Literature DB >> 24580083

What are our pharmacotherapeutic options for MERS-CoV?

Jaffar A Al-Tawfiq1, Ziad A Memish.   

Abstract

Since the initial description of Middle East Respiratory Syndrome-coronavirus (MERS-CoV), the disease has been associated with a high case-fatality rate. There is a lack of proven effective medications for therapy of MERS-CoV. The current knowledge of therapeutic options for MERS-CoV is based on the experience from SARS-CoV and from in vitro studies. In this article we review the different therapeutics available for MERS-CoV from SARS experience, in vitro and animal studies of this emerging disease.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24580083     DOI： 10.1586/17512433.2014.890515

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN： 1751-2433            Impact factor:   5.045


  12 in total

1.  Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.

Authors:  Mizuki Yamamoto; Shutoku Matsuyama; Xiao Li; Makoto Takeda; Yasushi Kawaguchi; Jun-Ichiro Inoue; Zene Matsuda
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

2.  Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis.

Authors:  Jason Kindrachuk; Britini Ork; Brit J Hart; Steven Mazur; Michael R Holbrook; Matthew B Frieman; Dawn Traynor; Reed F Johnson; Julie Dyall; Jens H Kuhn; Gene G Olinger; Lisa E Hensley; Peter B Jahrling
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

Review 3.  Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control.

Authors:  Prasannavenkatesh Durai; Maria Batool; Masaud Shah; Sangdun Choi
Journal:  Exp Mol Med       Date:  2015-08-28       Impact factor: 8.718

Review 4.  Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives.

Authors:  Ahmad Sharif-Yakan; Souha S Kanj
Journal:  PLoS Pathog       Date:  2014-12-04       Impact factor: 6.823

5.  Knowledge and attitude of healthcare workers about Middle East Respiratory Syndrome in multispecialty hospitals of Qassim, Saudi Arabia.

Authors:  Muhammad Umair Khan; Shahjahan Shah; Akram Ahmad; Omotayo Fatokun
Journal:  BMC Public Health       Date:  2014-12-16       Impact factor: 3.295

Review 6.  Aptamers in diagnostics and treatment of viral infections.

Authors:  Tomasz Wandtke; Joanna Woźniak; Piotr Kopiński
Journal:  Viruses       Date:  2015-02-16       Impact factor: 5.048

7.  Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.

Authors:  Jin Soo Shin; Eunhye Jung; Meehyein Kim; Ralph S Baric; Yun Young Go
Journal:  Viruses       Date:  2018-05-24       Impact factor: 5.048

8.  Middle East respiratory syndrome-related knowledge, preventive behaviours and risk perception among nursing students during outbreak.

Authors:  Ji Soo Kim; Jeong Sil Choi
Journal:  J Clin Nurs       Date:  2016-06-07       Impact factor: 3.036

Review 9.  Middle East respiratory syndrome coronavirus "MERS-CoV": current knowledge gaps.

Authors:  G R Banik; G Khandaker; H Rashid
Journal:  Paediatr Respir Rev       Date:  2015-04-18       Impact factor: 2.726

10.  Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).

Authors:  Joshua White
Journal:  Clin Microbiol Newsl       Date:  2014-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.